29 Mar 2018 07:00
Premaitha Health plc
("Premaitha" or the "Company")
Premaitha to attend key industry conferences in Asia Pacific
Manchester, UK - 29 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, is pleased to announce it will be participating in key industry conferences in the Asia Pacific ("APAC") region to raise awareness of its non-invasive prenatal testing ("NIPT") solutions.
Med Lab Asia Pacific
Med Lab Asia Pacific will be held in Singapore on 2 to 4 April 2018. The Company's exhibition stand will be hosted by members of the commercial teams from both Premaitha and Yourgene, with the central aim of promoting the technical benefits of the Sage™ prenatal workflow and analysis tools, as well as the regulated IONA® test, to clinical laboratories and our APAC distribution network.
For further details, please visit: www.medlabasia.com
ASPIRE 2018
Premaitha will also be hosting an exhibition booth at the eighth congress of the Asia Pacific Initiative on Reproduction ("ASPIRE 2018"), which will be held in Taiwan from 12 to 15 April 2018. The Company will be promoting both its IONA® and Sage™ prenatal screening solutions, as well as Yourgene Laboratory Services tests, including the preimplantation genetic screening ("PGS") service which is available at the Company's laboratory in Taipei.
For further details, please visit: www.aspire2018.com
RCOG 2018
Premaitha also recently attended The Royal College of Obstetricians and Gynaecologists World Congress, held in Singapore from 21 to 24 March 2018. The conference was attended by over 2000 obstetricians and gynaecologists.
In addition to participation in these major industry conferences, the Company continues to host smaller regional educational events in conjunction with Premaitha's hospital and laboratory customers to educate healthcare professionals on the clinical and technical aspects of our prenatal screening products and services.
Dr Stephen Little, CEO of Premaitha Health, commented: "We are very encouraged to see the continued update of NIPT across the Asia Pacific region. By attending these events, we are seeking to further raise awareness of our market leading solutions, as well as to strengthen our existing distribution networks in the region."
For more information, please contact:
| |
Premaitha Health PLCDr Stephen Little, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing investors@premaitha.com
| Tel: +44 (0)161 667 1053
|
finnCap (Broker) Adrian Hargrave / Scott Mathieson (Corporate Finance) Andrew Burdis / Abigail Wayne (Corporate Broking)
| Tel: +44 (0)20 7220 0500 |
Vigo Communications Ben Simons / Fiona Henson / Antonia Pollock premaitha@vigocomms.com
| Tel: +44 (0)20 7830 9700
|
About Premaitha
Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.
Premaitha's IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.
Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.